[Market Focus] Noel Falls 16% on News of 35 Billion Won Rights Offering

Noel is showing weakness in early trading.

As of 9:04 a.m. on September 25, Noel was trading at 2,935 won, down 16.38% (575 won) from the previous day. The decline in investor sentiment is attributed to the company's announcement of a large-scale paid-in capital increase.

Noel announced that its board of directors held a meeting the previous day and decided to raise capital through a rights offering for existing shareholders, followed by a public offering for forfeited shares, amounting to 35 billion won. Korea Investment & Securities will serve as the lead underwriter, proceeding with a standby underwriting method.

Noel stated that this capital increase aims to resolve short- and medium-term financial risks and accelerate global business growth. The funds raised will be used for the following purposes: 27.355 billion won for operating funds, 3 billion won for business acquisition, 2.645 billion won for facility investment, and 2 billion won for debt repayment.

The record date for new share allocation is October 31, 2025, and approximately 0.39 new shares will be allocated per existing share. The planned issue price is 2,440 won per share. The subscription period for existing shareholders is scheduled for December 4 to December 5, 2025, and the listing date for the new shares is expected to be December 30, 2025.

Noel is a company specializing in artificial intelligence (AI)-based blood and cancer diagnostics. It has developed 'MyLab,' an on-device AI medical device that automates the entire diagnostic process, and is expanding its product range to include malaria and cervical cancer diagnostics.

This content was produced with the assistance of AI translation services.